Entresto is a combination of sacubitril, an enkephalinase inhibitor, and valsartan, an angiotensin II receptor blocker, to reduce the risk of cardiovascular death and hospitalization in patients with heart failure, chronic heart failure (nyhaii-iv) and decreased ejection fraction.